D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.
Frequently asked questions
What sector does D&D PharmaTech Co. (347850) operate in?
D&D PharmaTech Co. belongs to the Other sector and operates in the Biotechnology industry.
What is D&D PharmaTech Co. (347850) current stock price?
As of the latest data, D&D PharmaTech Co. stock price is ₩61,700, with a previous close of ₩61,700.
What is D&D PharmaTech Co. (347850) current market capitalization?
D&D PharmaTech Co. market cap is approximately 2.70 trillion.
Does D&D PharmaTech Co. (347850) pay dividends?
No. D&D PharmaTech Co. does not pay a dividend.
What is D&D PharmaTech Co. (347850) beta (volatility) score?
D&D PharmaTech Co. has a beta of 1.641, suggesting it is more volatile than the market.
